Neurotoxicity De-Risking in Preclinical Drug Discovery

Objective

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.

Field of science

• /medical and health sciences/medical biotechnology/cells technologies/stem cells
• /natural sciences/computer and information sciences/artificial intelligence
• /natural sciences/biological sciences/neurobiology

Programme(s)

• H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

• IMI2-2017-13-10 - Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

Call for proposal

H2020-JTI-IMI2-2017-13-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

UNIVERSITAT WIEN

Address

Universitatsring 1
1010 Wien
Austria

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 594 450

Participants (17)

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU contribution

€ 372 200

Address

Spitalgasse 23
1090 Wien

Activity type

Higher or Secondary Education Establishments

FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU

Serbia

EU contribution

€ 696 150

Address

Vojvode Stepe 450
52600 Belgrade

Activity type

Higher or Secondary Education Establishments

INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH

Austria

EU contribution

€ 341 400

Address

Clemens Maria Hofbauer Gasse 6
2344 Maria Enzersdorf

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

ITA-SUOMEN YLIOPISTO

Finland

EU contribution

€ 804 900

Address

Yliopistonranta 1 E
70211 Kuopio

Activity type

Higher or Secondary Education Establishments

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU contribution

€ 391 500

Address

Piazza San Marco 4
50121 Florence

Activity type

Higher or Secondary Education Establishments

ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO

Portugal

EU contribution

€ 403 500

Address

Rua D Manuel Ii Apartado 55142
4051 401 Porto

Activity type

Research Organisations

UPPSALA UNIVERSITET

Sweden

EU contribution

€ 307 400

Address

Von Kraemers Alle 4
751 05 Uppsala

Activity type

Higher or Secondary Education Establishments

ALCEDIAG

France

EU contribution

€ 583 300

Address

Route Des Michels La Corneirelle
13790 Peynier

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

UNIVERSITE CLERMONT AUVERGNE

France

EU contribution

€ 429 400

Address

49 Boulevard Francois Mitterrand
63000 Clermont-ferrand

Activity type

Higher or Secondary Education Establishments

A. PERSIDIS & SIA OE

Greece

EU contribution

€ 406 800

Address

Rodopoleos Street 34
167 77 Athina

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

EU contribution

€ 0

Address

Pierre Brossolette 1
91380 Chilly Mazarin

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

ASTRAZENECA AB

Sweden

EU contribution

€ 0

Address

Vastra Maelarhamnen
151 85 Sodertaelje

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

FUJIFILM CELLULAR DYNAMICS INC

United States

EU contribution

€ 0

Address

Science Drive 525 Suite 200
53711 Madison Wi

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

MERCK SHARP & DOHME CORP

United States

EU contribution

€ 0

Address

One Merck Drive
08889 Whitehouse Station Nj

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

NOVARTIS PHARMA AG

Switzerland

EU contribution

€ 0

Address

Lichtstrasse 35
4056 Basel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

PFIZER LIMITED

United Kingdom

EU contribution

€ 0

Address

Ramsgate Road
CT13 9NJ Sandwich

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

UCB BIOPHARMA SRL

Belgium

EU contribution

€ 0

Address

Allee De La Recherche 60
1070 Bruxelles

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)